Y-MAbs Therapeutics' CEO Exits, Expects FY22 Danyelza Sales of Up To $50M

  • Y-mAbs Therapeutics Inc's YMAB CEO and Board Member, Claus Moller, has stepped down from his position effective immediately. 
  • Thomas Gad, the Company's Founder, Chairman & President, has assumed the interim CEO and Board Member role. 
  • In addition, Mr. Gad has stepped down as Chairman, and Jim Healy, current Board Member and Chair of the Compensation Committee, has been appointed as Chairman of the Board. 
  • The Company posted preliminary Q1 FY22 Danyelza sales of $10.5 million, with a $45-50 million full-year revenue guidance. 
  • The omburtamab FDA marketing application was resubmitted in March and is currently under review with the FDA. 
  • The Company held a cash balance of $156.7 million, which provides a runway to mid-2024. 
  • For 2022, Y-mAbs expects operating expenses of $162-167 million and a net cash burn of $78-83 million.
  • Price Action: YMAB shares closed at $9.35 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapManagementGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!